| 1 |
34985925 | Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. | 2022 Feb 20 |
1 |
| 2 |
35170879 | Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis. | 2022 Feb 16 |
1 |
| 3 |
35356229 | Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor. | 2022 |
1 |
| 4 |
32361873 | VEGF inhibition in urothelial cancer: the past, present and future. | 2021 Mar |
1 |
| 5 |
32954856 | Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. | 2021 Feb |
2 |
| 6 |
33078505 | Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab. | 2021 Jan |
1 |
| 7 |
33080152 | Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. | 2021 Mar |
3 |
| 8 |
33355035 | Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. | 2021 Feb |
2 |
| 9 |
33382454 | Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials. | 2021 May |
1 |
| 10 |
33523301 | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. | 2021 Aug |
1 |
| 11 |
33855690 | Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. | 2021 May |
2 |
| 12 |
33869015 | Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials. | 2021 |
1 |
| 13 |
34620772 | The emerging treatment landscape of advanced urothelial carcinoma. | 2021 Dec 1 |
1 |
| 14 |
34767024 | Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. | 2021 Nov 1 |
1 |
| 15 |
34792359 | α-MoC Supported Noble Metal Catalysts for Water-Gas Shift Reaction: Single-Atom Promoter or Single-Atom Player. | 2021 Nov 25 |
1 |
| 16 |
31506751 | Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. | 2020 Jan |
1 |
| 17 |
31761899 | Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. | 2020 Feb |
1 |
| 18 |
32197264 | Pt nanoparticles anchored on rare metal oxide coated on SBA-15: a highly active catalyst for synergistic catalytic hydrogenation of benzaldehyde. | 2020 May 1 |
1 |
| 19 |
32670420 | Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. | 2020 |
2 |
| 20 |
32947924 | Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials. | 2020 Sep 16 |
1 |
| 21 |
30565086 | SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). | 2019 Jan |
1 |
| 22 |
31074244 | Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. | 2019 Jul |
1 |
| 23 |
31200951 | Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. | 2019 Dec |
3 |
| 24 |
31240480 | Approach to the Patient with Recurrent/Metastatic Disease. | 2019 Jun 25 |
1 |
| 25 |
31593831 | Immune gene expression in head and neck squamous cell carcinoma patients. | 2019 Nov |
2 |
| 26 |
31671550 | Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma. | 2019 Oct 30 |
1 |
| 27 |
31676812 | Quasi Pd1Ni single-atom surface alloy catalyst enables hydrogenation of nitriles to secondary amines. | 2019 Nov 1 |
1 |
| 28 |
33014516 | Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. | 2019 Mar |
1 |
| 29 |
29325739 | Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. | 2018 Apr |
1 |
| 30 |
29502288 | Immunotherapy for Head and Neck Squamous Cell Carcinoma. | 2018 Mar 3 |
1 |
| 31 |
29650143 | Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. | 2018 May |
1 |
| 32 |
30275703 | PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. | 2018 |
1 |
| 33 |
30482243 | Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. | 2018 Nov 27 |
1 |
| 34 |
28636292 | [Head and neck cancer : promising results of immunotherapy]. | 2017 May 17 |
1 |
| 35 |
27313464 | Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. | 2016 |
1 |
| 36 |
26351349 | Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. | 2015 Dec 1 |
1 |